# reload+after+2024-01-21 18:47:11.065859
address1§155 Bovet Road
address2§Suite 303
city§San Mateo
state§CA
zip§94402
country§United States
phone§650-561-8600
website§https://sagimet.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
fullTimeEmployees§9
companyOfficers§[{'maxAge': 1, 'name': 'Dr. George W. Kemble Ph.D.', 'age': 62, 'title': 'Executive Chairman of the Board', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 444856, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. David A. Happel', 'age': 61, 'title': 'CEO, President & Director', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 309417, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Eduardo Bruno Martins DPhil, M.D., Ph.D.', 'age': 60, 'title': 'Chief Medical Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 536833, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Urs  Greber Ph.D.', 'title': 'Co-Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Lucas  Pelkmans Ph.D.', 'title': 'Co-Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Elizabeth  Rozek J.D.', 'age': 52, 'title': 'General Counsel & Chief Compliance Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': "Dr. Marie  O'Farrell Ph.D.", 'title': 'Senior Vice President of Research & Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
priceToSalesTrailing12Months§54.83568
currency§USD
dateShortInterest§1702598400
forwardEps§-2.27
exchange§NGM
quoteType§EQUITY
shortName§Sagimet Biosciences Inc. - Seri
longName§Sagimet Biosciences Inc.
firstTradeDateEpochUtc§1689600600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§036364bd-80e6-3704-a7f9-b8281c4b4a2f
gmtOffSetMilliseconds§-18000000
targetHighPrice§67.0
targetLowPrice§30.0
targetMeanPrice§42.67
targetMedianPrice§31.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§3
quickRatio§20.171
grossMargins§1.0
ebitdaMargins§0.0
trailingPegRatio§None
